Lung Cancer

Lung cancer is a heterogenous disease compromising of several subtypes including non-small cell lung carcinoma (NSCLC), adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Recent advances in molecular techniques has enabled the identification of molecular abnormalities leading to emergence of personalized treatment strategies.

Mutations, gene rearrangements, amplification and deletion are the main molecular alteration seen in lung cancer.

biosimilars

Key NSCLC biomarkers

EGFR ALK ROS1 HER2 RET MET BRAF PIK3CA NTRK1 FGFR DDR2

Key Adenocarcinoma biomarkers

KRAS EGFR MET ALK NTRK1 FGFR HER2 ROS BRAF PIK3CA RET DDR1

Key Squamous Cell Carcinoma biomarkers

FGFR PTEN PIK3CA KRAS DDR2 EGFR MET

Lung cancer tissue controls

Frozen sections Tissue Protein Lysates Total RNA FFPE sections Genomic DNA Tissue Scan

In addition to other tools, OriGene has the largest collection Mutant ORF Clones, Ultra specific antibodies (UltraMAB), CytoSections (Control for IHC, ICC) and other tools for genes associated with lung cancer.

Mutant ORF clones Ultra-Specific Antibodies & other monoclonals CytoSections
(Verified controls for IHC, ICC) 		Other tools
KRAS Mutant ORF clones KRAS Ultra-specific antibodies KRAS CytoSections KRAS tools
EGFR Mutant ORF clones EGFR Ultra-specific antibodies EGFR CytoSections EGFR tools
MET Mutant ORF clones MET Ultra-specific antibodies MET CytoSections MET tools
ALK Mutant ORF clones ALK Ultra-specific antibodies ALK CytoSections ALK tools
FGFR Mutant ORF clones FGFR Ultra-specific antibodies FGFR CytoSections FGFR tools
HER2 Mutant ORF clones HER2 Ultra-specific antibodies HER2 CytoSections HER2 tools
BRAF Mutant ORF clones BRAF Ultra-specific antibodies BRAF CytoSections BRAF tools
RET Mutant ORF clones RET Ultra-specific antibodies RET CytoSections RET tools
DDR2 Mutant ORF clones DDR2 Ultra-specific antibodies DDR2 CytoSections DDR2 tools
PTEN Mutant ORF clones PTEN Ultra-specific antibodies PTEN CytoSections PTEN tools
PIK3CA Mutant ORF clones PIK3CA Ultra-specific antibodies PIK3CA CytoSections PIK3CA tools

References:

  1. Villalobos et al, 2017 Feb; 31(1): 13–29. doi: 10.1016/j.hoc.2016.08.006
  2. Pakkala et al., 2018 Aug 9;3(15):e120858.  doi:10.1172/jci.insight.120858
  3. Goebel et al.; 2020 July 1 11 (7): doi:10.1039/d0md00096e
  4. Ryan et al., 2018 Nov 15 (11): doi:10.1038/s41571-018-0105-0
  5. Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. Int J Mol Sci. 2017 Jan 19;18(1):197. doi:10.3390/ijms18010197 PMID: 28106826; PMCID: PMC5297828.https://pubmed.ncbi.nlm.nih.gov/28106826/.